Five week-old mice were divided into a vehicle control group, and groups exposed to ZnO nanoparticles at low (0.5 g/kg), middle (1 g/kg), high (3g/kg) and exceptionally high-dose (5 g/kg). After the 1 st , 2 nd , 3 rd and 4 th weeks of exposure, blood biochemistry, histopathology, and electron microscopic ultrastructural changes in liver, kidney and spleen were investigated. Increased alkaline phosphatase activities were observed in all treated mice being statistically significant at higher dose. No changes were observed in the serum glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase, creatinine, blood urea nitrogen and ,lipid levels. During the 1 st and 2 nd week of treatment, effects on the cytoarchitecture of liver, kidney and spleen were not perceived while during the 3 rd and 4 th week of treatment sporadic mild effects were seen. Ultrastructural electron microscopic changes in liver, kidney and spleen were not observed for the low-dose group onthe 1 st , 2 nd , 3 rd and 4 th week, suggesting that exposure to ZnO nanoparticles at low dose is safe. Long term (i.e, more than 28 days) exposure to the exceptionally high-dose resulted in sporadic changes in nuclear chromatin condensation, irregular nuclear membrane, polymorphic mitochondria, mitochondrial swelling and vacuolation. ZnO nanoparticles could be well tolerated and no death occurred in any group of treated mice.